Abstract
Refining the indication for adjuvant pembrolizumab in patients with clear cell renal cell carcinoma at high risk of recurrence using a risk-adapted approach: A contemporary multicentre study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have